Last reviewed · How we verify
EG12014
EG12014 is a monoclonal antibody targeting CD19.
EG12014 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | EG12014 |
|---|---|
| Sponsor | EirGenix, Inc. |
| Drug class | Monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This leads to a reduction in B cell count and subsequent decrease in disease activity.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (PHASE1, PHASE2)
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (PHASE2)
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis (PHASE4)
- Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (PHASE3)
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EG12014 CI brief — competitive landscape report
- EG12014 updates RSS · CI watch RSS
- EirGenix, Inc. portfolio CI